{"protocolSection": {"identificationModule": {"nctId": "NCT01692301", "orgStudyIdInfo": {"id": "CLCZ696A2216"}, "secondaryIdInfos": [{"id": "2012-002899-14", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension", "officialTitle": "A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension"}, "statusModule": {"statusVerifiedDate": "2016-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-12"}, "primaryCompletionDateStruct": {"date": "2015-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-09-20", "studyFirstSubmitQcDate": "2012-09-20", "studyFirstPostDateStruct": {"date": "2012-09-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-31", "resultsFirstSubmitQcDate": "2016-03-31", "resultsFirstPostDateStruct": {"date": "2016-05-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-03-31", "lastUpdatePostDateStruct": {"date": "2016-05-04", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated systolic blood pressure (SBP) and widened pulse pressure (PP)."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["hypertension, elderly, central aortic pulse pressure, central pulse pressure, pulse wave velocity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 454, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696 (sacubitril/valsartan)", "type": "EXPERIMENTAL", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.", "interventionNames": ["Drug: LCZ696", "Drug: LCZ696 matching placebo", "Drug: Olmesartan matching placebo", "Drug: amlodipine", "Drug: hydrochlorothiazide"]}, {"label": "Olmesartan", "type": "ACTIVE_COMPARATOR", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.", "interventionNames": ["Drug: Olmesartan", "Drug: LCZ696 matching placebo", "Drug: amlodipine", "Drug: hydrochlorothiazide"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "200 mg tablet", "armGroupLabels": ["LCZ696 (sacubitril/valsartan)"], "otherNames": ["sacubitril/valsartan"]}, {"type": "DRUG", "name": "Olmesartan", "description": "20 mg and 40 mg capsules", "armGroupLabels": ["Olmesartan"]}, {"type": "DRUG", "name": "LCZ696 matching placebo", "description": "LCZ696 Matching Placebo tablet", "armGroupLabels": ["LCZ696 (sacubitril/valsartan)", "Olmesartan"]}, {"type": "DRUG", "name": "Olmesartan matching placebo", "description": "Olmesartan matching placebo capsule", "armGroupLabels": ["LCZ696 (sacubitril/valsartan)"]}, {"type": "DRUG", "name": "amlodipine", "description": "amlodipine 2.5 mg or 5 mg tablets", "armGroupLabels": ["LCZ696 (sacubitril/valsartan)", "Olmesartan"]}, {"type": "DRUG", "name": "hydrochlorothiazide", "description": "hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets", "armGroupLabels": ["LCZ696 (sacubitril/valsartan)", "Olmesartan"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks", "description": "Central aortic blood pressure was derived from peripheral pressure waveforms recorded noninvasively from the brachial artery using a cuff-based device. This technique uses the brachial pressure and a signal processing algorithm to transform brachial signals into central blood pressure (BP) waveforms. When the aortic pressure waveform was derived, key pulse wave analysis (PWA) parameters, such as CASP was calculated by the system software.\n\nAt the first study visit, the arm with the highest systolic blood pressure (SBP) was used for all subsequent PWA. Brachial PWA measurements were performed on the same arm that the office blood pressures were taken. Two pulse waveform measurements, meeting all quality control criteria were captured at baseline and at week 12 visits.", "timeFrame": "baseline, 12 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Central Pulse (CPP) Pressure", "timeFrame": "Baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean Pulse Wave Velocity (PWV)", "description": "Pulse wave velocity recordings were performed on patient while in a supine, face-up position.\n\nTonometry was performed on the carotid simultaneously with the cuff inflation over the femoral artery. Two pulse wave velocity measures, meeting all quality control criteria were captured at baseline, week 12 and week 52.", "timeFrame": "baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks", "description": "Central aortic blood pressure was derived from peripheral pressure waveforms recorded noninvasively from the brachial artery using a cuff-based device. This technique uses the brachial pressure and a signal processing algorithm to transform brachial signals into central blood pressure (BP) waveforms. When the aortic pressure waveform was derived, key pulse wave analysis (PWA) parameters, such as CASP was calculated by the system software.\n\nAt the first study visit, the arm with the highest systolic blood pressure (SBP) was used for all subsequent PWA. Brachial PWA measurements were performed on the same arm that the office blood pressures were taken. Two pulse waveform measurements, meeting all quality control criteria were captured at baseline and at week 12 visits.", "timeFrame": "baseline, 52 weeks"}, {"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "timeFrame": "baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, DBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "timeFrame": "baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean Sitting Pulse Pressure (msPP)", "description": "Mean sitting pulse pressure for each patient and visit was calculated as the difference between the calculated values of mean sitting systolic blood pressure and mean sitting diastolic blood pressure.", "timeFrame": "baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean Arterial Pressure (MAP)", "description": "Mean arterial pressure (MAP) was calculated from mean sitting systolic BP (msSBP) and mean sitting diastolic BP (msDBP) as (2 \\* msDBP + msSBP)/3.", "timeFrame": "baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)", "description": "An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit. The 24 hour maSBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period.", "timeFrame": "Baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)", "description": "An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit. The 24 hour maDBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period.", "timeFrame": "Baseline, 12 weeks, and 52 weeks"}, {"measure": "Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)", "description": "Mean 24 hour ambulatory pulse pressure was calculated as the difference between the mean 24 hour systolic and diastolic ambulatory blood pressure in corresponding visits i.e. baseline, week 12 and week 52.", "timeFrame": "Baseline, 12 weeks, and 52 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Male and female patients \u2265 60 years of age.\n2. Patients with essential hypertension, untreated or currently taking antihypertensive therapy.\n3. Untreated patients must have an office msSBP \u2265150 mmHg and \\<180 mmHg at Visit 101 and Visit 201 if they are newly diagnosed or have not been treated with antihypertensive drugs for the 4 weeks prior to Visit 1.\n4. Treated patients must have an office msSBP \u2265140 mmHg and \\<180 mmHg at Visit 102 (or Visit 103) and msSBP \u2265150 mmHg and \\<180 mmHg at Visit 201 if they have been treated with antihypertensive drugs for the 4 weeks prior to Visit 1.\n5. All patients must have pulse pressure \\>60 mmHg at Visit 201. Pulse pressure is defined as msSBP- msDBP.\n6. Patients must have a difference in msSBP within +/-15 mmHg between Visit 201 (randomization) and the visit immediately prior to Visit 201.\n\nKey Exclusion Criteria:\n\n1. Malignant or severe hypertension (grade 3 of WHO classification; msDBP \u2265110 mmHg and/or msSBP \u2265 180 mmHg)\n2. History of angioedema, drug-related or otherwise.\n3. History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension.\n4. Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke.\n5. History of myocardial infarction, coronary bypass surgery or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit 1.\n6. History of atrial fibrillation or atrial flutter during the 3 months prior to Visit 1, or active atrial fibrillation or atrial flutter on the ECG at screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "60 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Novartis Investigative Site", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novartis Investigative Site", "city": "Baltimore", "state": "Maryland", "zip": "21204", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novartis Investigative Site", "city": "Belzoni", "state": "Mississippi", "zip": "39038", "country": "United States", "geoPoint": {"lat": 33.18429, "lon": -90.48926}}, {"facility": "Novartis Investigative Site", "city": "Jackson", "state": "Mississippi", "zip": "39209", "country": "United States", "geoPoint": {"lat": 32.29876, "lon": -90.18481}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Novartis Investigative Site", "city": "Cincinnati", "state": "Ohio", "zip": "45224", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Lake Jackson", "state": "Texas", "zip": "77566", "country": "United States", "geoPoint": {"lat": 29.03386, "lon": -95.43439}}, {"facility": "Novartis Investigative Site", "city": "Pasadena", "state": "Texas", "zip": "77504", "country": "United States", "geoPoint": {"lat": 29.69106, "lon": -95.2091}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Buenos Aires", "zip": "C1440AAD", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Ramos Mejia", "state": "Buenos Aires", "zip": "B1704ETD", "country": "Argentina", "geoPoint": {"lat": -34.6551, "lon": -58.55318}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000CXH", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "Barranquilla", "state": "Atlantico", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Novartis Investigative Site", "city": "Barranquilla", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"facility": "Novartis Investigative Site", "city": "Paris", "zip": "75015", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Nuernberg", "zip": "90471", "country": "Germany", "geoPoint": {"lat": 49.45421, "lon": 11.07752}}, {"facility": "Novartis Investigative Site", "city": "Athens", "zip": "11525", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Novartis Investigative Site", "city": "Athens", "zip": "11526", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Novartis Investigative Site", "city": "Thessaloniki", "zip": "54642", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novartis Investigative Site", "city": "Treviglio", "state": "BG", "zip": "24047", "country": "Italy", "geoPoint": {"lat": 45.52081, "lon": 9.59102}}, {"facility": "Novartis Investigative Site", "city": "Pisa", "state": "PI", "zip": "56126", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Novartis Investigative Site", "city": "San Daniele Del Friuli", "state": "UD", "zip": "33038", "country": "Italy", "geoPoint": {"lat": 46.15714, "lon": 13.00726}}, {"facility": "Novartis Investigative Site", "city": "Shimotsuke-city", "state": "Tochigi", "zip": "329-0498", "country": "Japan", "geoPoint": {"lat": 36.41323, "lon": 139.86622}}, {"facility": "Novartis Investigative Site", "city": "Bucheon", "state": "Gyeonggi-do", "zip": "424-717", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Korea", "zip": "110 744", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "101990", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "117198", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "119992", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Saint Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint-Petersburg", "zip": "197341", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Yaroslavl", "zip": "150047", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Novartis Investigative Site", "city": "Sevilla", "state": "Andalucia", "zip": "41071", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novartis Investigative Site", "city": "Jerez de La Frontera", "state": "Cadiz", "zip": "11407", "country": "Spain", "geoPoint": {"lat": 36.68645, "lon": -6.13606}}, {"facility": "Novartis Investigative Site", "city": "Barcelona", "state": "Cataluna", "zip": "08003", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigative Site", "city": "Barcelona", "state": "Catalunya", "zip": "08025", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigative Site", "city": "Terrassa", "state": "Catalunya", "zip": "08221", "country": "Spain", "geoPoint": {"lat": 41.56667, "lon": 2.01667}}, {"facility": "Novartis Investigative Site", "city": "Centelles", "state": "Catalu\u00f1a", "zip": "08540", "country": "Spain", "geoPoint": {"lat": 41.79746, "lon": 2.21902}}, {"facility": "Novartis Investigative Site", "city": "Puerto de Sagunto", "state": "Comunidad Valenciana", "zip": "46520", "country": "Spain"}, {"facility": "Novartis Investigative Site", "city": "La Coruna", "state": "Galicia", "zip": "15706", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28034", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28041", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "state": "Taiwan, ROC", "zip": "112", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Novartis Investigative Site", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Novartis Investigative Site", "city": "Taipei", "zip": "114", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}, "referencesModule": {"references": [{"pmid": "24496699", "type": "DERIVED", "citation": "Williams B, Cockcroft JR, Kario K, Zappe DH, Cardenas P, Hester A, Brunel P, Zhang J. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open. 2014 Feb 4;4(2):e004254. doi: 10.1136/bmjopen-2013-004254."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "FG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "\"Started\" indicates patients in randomized, full analysis and safety set", "numSubjects": "229"}, {"groupId": "FG001", "numSubjects": "225"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "184"}, {"groupId": "FG001", "numSubjects": "183"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "42"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Non-compliance with study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Patient/guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Technical problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set - All patients who were randomized.", "groups": [{"id": "BG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "BG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "229"}, {"groupId": "BG001", "value": "225"}, {"groupId": "BG002", "value": "454"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68.2", "spread": "5.73"}, {"groupId": "BG001", "value": "67.2", "spread": "5.97"}, {"groupId": "BG002", "value": "67.7", "spread": "5.87"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "107"}, {"groupId": "BG002", "value": "217"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "119"}, {"groupId": "BG001", "value": "118"}, {"groupId": "BG002", "value": "237"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks", "description": "Central aortic blood pressure was derived from peripheral pressure waveforms recorded noninvasively from the brachial artery using a cuff-based device. This technique uses the brachial pressure and a signal processing algorithm to transform brachial signals into central blood pressure (BP) waveforms. When the aortic pressure waveform was derived, key pulse wave analysis (PWA) parameters, such as CASP was calculated by the system software.\n\nAt the first study visit, the arm with the highest systolic blood pressure (SBP) was used for all subsequent PWA. Brachial PWA measurements were performed on the same arm that the office blood pressures were taken. Two pulse waveform measurements, meeting all quality control criteria were captured at baseline and at week 12 visits.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoint (week 12).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 12 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "206"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.57", "spread": "1.01"}, {"groupId": "OG001", "value": "-8.90", "spread": "1.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.010", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-3.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.45", "ciUpperLimit": "-0.87", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.42"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Central Pulse (CPP) Pressure", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoint (week 12, week 52). Four patients did not have a successful CASP assessment at Week 12 but passed quality check at Week 52, thus 4 more patients were included in the Week 52 Endpoint analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to Week 12 (n = 207, 206)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.41", "spread": "0.69"}, {"groupId": "OG001", "value": "-3.96", "spread": "0.69"}]}]}, {"title": "Baseline to Week 52 (n = 209, 208)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.16", "spread": "0.69"}, {"groupId": "OG001", "value": "-6.65", "spread": "0.69"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Pulse Wave Velocity (PWV)", "description": "Pulse wave velocity recordings were performed on patient while in a supine, face-up position.\n\nTonometry was performed on the carotid simultaneously with the cuff inflation over the femoral artery. Two pulse wave velocity measures, meeting all quality control criteria were captured at baseline, week 12 and week 52.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoint (week 12 , week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "meter/second", "timeFrame": "baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to week 12 (n= 192, 196)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "0.12"}, {"groupId": "OG001", "value": "-0.57", "spread": "0.12"}]}]}, {"title": "Baseline to week 52 ( n= 199, 199)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "0.13"}, {"groupId": "OG001", "value": "0.77", "spread": "0.13"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks", "description": "Central aortic blood pressure was derived from peripheral pressure waveforms recorded noninvasively from the brachial artery using a cuff-based device. This technique uses the brachial pressure and a signal processing algorithm to transform brachial signals into central blood pressure (BP) waveforms. When the aortic pressure waveform was derived, key pulse wave analysis (PWA) parameters, such as CASP was calculated by the system software.\n\nAt the first study visit, the arm with the highest systolic blood pressure (SBP) was used for all subsequent PWA. Brachial PWA measurements were performed on the same arm that the office blood pressures were taken. Two pulse waveform measurements, meeting all quality control criteria were captured at baseline and at week 12 visits.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoint (week 52). Four patients did not have a successful CASP assessment at Week 12 but passed quality check at Week 52, thus 4 more patients were included in the Week 52 Endpoint analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.18", "spread": "0.96"}, {"groupId": "OG001", "value": "-14.70", "spread": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)", "description": "At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoints (week 12, week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to week 12 (n=226, 222)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.84", "spread": "1.06"}, {"groupId": "OG001", "value": "-14.57", "spread": "1.07"}]}]}, {"title": "Baseline to week 52 (n=226,223)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.91", "spread": "0.98"}, {"groupId": "OG001", "value": "-21.45", "spread": "0.99"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, DBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoints (week 12, week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to week 12 (n=226, 222)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.86", "spread": "0.58"}, {"groupId": "OG001", "value": "-5.58", "spread": "0.59"}]}]}, {"title": "Baseline to week 52 (n=226,223)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.92", "spread": "0.57"}, {"groupId": "OG001", "value": "-7.85", "spread": "0.57"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Pulse Pressure (msPP)", "description": "Mean sitting pulse pressure for each patient and visit was calculated as the difference between the calculated values of mean sitting systolic blood pressure and mean sitting diastolic blood pressure.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoints (week 12, week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to week 12 (n=226,222)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.13", "spread": "0.82"}, {"groupId": "OG001", "value": "-8.86", "spread": "0.82"}]}]}, {"title": "Baseline to week 52 (n= 226, 223)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.02", "spread": "0.79"}, {"groupId": "OG001", "value": "-13.58", "spread": "0.80"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Arterial Pressure (MAP)", "description": "Mean arterial pressure (MAP) was calculated from mean sitting systolic BP (msSBP) and mean sitting diastolic BP (msDBP) as (2 \\* msDBP + msSBP)/3.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoints (week 12, week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to week 12 (n=226, 222)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.19", "spread": "0.68"}, {"groupId": "OG001", "value": "-8.57", "spread": "0.68"}]}]}, {"title": "Baseline to week 52 (n=226, 223)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.92", "spread": "0.63"}, {"groupId": "OG001", "value": "-12.38", "spread": "0.64"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)", "description": "An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit. The 24 hour maSBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoints (week 12, week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to week 12 (n= 164, 162)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.25", "spread": "0.62"}, {"groupId": "OG001", "value": "-9.14", "spread": "0.62"}]}]}, {"title": "Baseline to week 52 (n= 174, 176)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.15", "spread": "0.59"}, {"groupId": "OG001", "value": "-14.32", "spread": "0.58"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)", "description": "An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit. The 24 hour maDBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoints (week 12, week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to week 12 (n= 164, 162)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.44", "spread": "0.37"}, {"groupId": "OG001", "value": "-5.48", "spread": "0.36"}]}]}, {"title": "Baseline to week 52 (n= 174, 176)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.85", "spread": "0.35"}, {"groupId": "OG001", "value": "-8.44", "spread": "0.34"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)", "description": "Mean 24 hour ambulatory pulse pressure was calculated as the difference between the mean 24 hour systolic and diastolic ambulatory blood pressure in corresponding visits i.e. baseline, week 12 and week 52.", "populationDescription": "Full analysis set (FAS): All patients who were randomized. This endpoint included number of patients who had values at both baseline and endpoints (week 12, week 52).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 12 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study."}, {"id": "OG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "225"}]}], "classes": [{"title": "Baseline to Week 12 (n=164, 162 )", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.77", "spread": "0.35"}, {"groupId": "OG001", "value": "-3.69", "spread": "0.35"}]}]}, {"title": "Baseline to week 52 (n=174, 176)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.26", "spread": "0.36"}, {"groupId": "OG001", "value": "-5.91", "spread": "0.35"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "LCZ696 (Sacubitril/Valsartan)", "description": "Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.", "seriousNumAffected": 16, "seriousNumAtRisk": 229, "otherNumAffected": 73, "otherNumAtRisk": 229}, {"id": "EG001", "title": "Olmesartan", "description": "Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.", "seriousNumAffected": 13, "seriousNumAtRisk": 225, "otherNumAffected": 55, "otherNumAtRisk": 225}], "seriousEvents": [{"term": "ANAEMIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "COAGULOPATHY", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "IRON DEFICIENCY ANAEMIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "ACUTE CORONARY SYNDROME", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "ACUTE MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "ANGINA PECTORIS", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "ANGINA UNSTABLE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "CARDIO-RESPIRATORY ARREST", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "SUPRAVENTRICULAR TACHYCARDIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "CATARACT", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "INGUINAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "CHOLECYSTITIS CHRONIC", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "CHOLELITHIASIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "APPENDICITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "DOUGLAS' ABSCESS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "PERITONITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "HIP FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "PULMONARY CONTUSION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "RIB FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 225}]}, {"term": "ROAD TRAFFIC ACCIDENT", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "SPINAL FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "SUBDURAL HAEMORRHAGE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "TENDON RUPTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "UPPER LIMB FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "VASCULAR GRAFT OCCLUSION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "BLOOD PRESSURE INCREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "OSTEOCHONDROSIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "SQUAMOUS CELL CARCINOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "BRAIN STEM INFARCTION", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "ISCHAEMIC STROKE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "ATELECTASIS", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "PNEUMOTHORAX", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "PULMONARY EMBOLISM", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}, {"term": "PULMONARY PNEUMATOCELE", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "RESPIRATORY FAILURE", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "HYPERTENSIVE CRISIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "ORTHOSTATIC HYPOTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}]}], "otherEvents": [{"term": "ABDOMINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 225}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 225}]}, {"term": "OEDEMA PERIPHERAL", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 225}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 225}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 225}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 225}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 225}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 225}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 225}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 225}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 225}]}, {"term": "HYPOTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 229}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 225}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Directors", "organization": "Novartis Pharmaceuticals", "email": "trialandresults.registries@novartis.com", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Brazil"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M4854", "name": "Benzocaine", "relevance": "LOW"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "T433", "name": "Tannic Acid", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}